About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
Tractaments combinats per prevenir les lesions o fibrosis hepàtica en malaltia hepàtica crònica/NASH
Tractaments dirigits a cèl·lules sinusoïdals hepàtiques a través de nanopartícules biodegradables
Desenvolupament de models animals experimentals translacionals a la patologia en humans de NASH i malaltia hepàtica per alcohol
Mètodes no invasius per malaltia hepàtica crònica avançada
Hipertensió portal
Serveis o tecnologies rellevants:
Models animals de malaltia hepàtica crònica: PVL; BDL; CCL4; TAA; NAFLD; NASH; MAFLD
Determinació de paràmetres hemodinàmics en models animals: PP; MAP; SMABF; SMAR, PF; IHVR
Aïllament de cèl·lules primàries de fetge: hepatòcits; LSEC; KC; HSC
Tincions histològiques
Cultius cel·lulars
Citometria de flux
Anàlisis de proteïnes: Wb, IIHC, IF, Proteòmica diferencial
Anàlisis d'expressió gènica: RT-qPCR, ISH, Microarrays
Microscòpia confocal i Microscòpia electrònica
Administració de fàrmacs en nanopartícules: Internalizació; direccionament; biodistribució; efectivitat; assaigs MTT y MTD
IP: Joan Genescà Ferrer
Malaltia avançada: hepatitis alcohòlica, cirrosis i malaltia hepàtica crònica per alcohol (cALD)
Salut pública
Insuficiència hepàtica aguda sobre crònica (ACLF)
IP: Meritxell Ventura Cots
Malalties colestàsiques
Complicacions de la cirrosi hepàtica
IP: Malalties hepàtiques cròniques
Epidemiologia del fetge gras no alcohòlic, biomarcadors i nous tractament
Infeccions malaltia hepàtica avançada
IP: Juan Manuel Pericàs Pulido
IP: José Raul Herance Camacho Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericàs Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Alberto Roque Pérez, ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients, Maria Nazarena Pizzi, Ramón Vilallonga Puy, Enrique Franky Vargas, Carolina Aparicio Gomez Funding agency: EUROPEAN COMMISSION Funding: 724000 Reference: ARTEMIS_HE-HLTH2023 Duration: 01/01/2024 - 31/12/2027
IP: Josep Quer Sivila Collaborators: Marta Ibañez Lligoña, Miriam Izquierdo Sans Funding agency: Fundació "La Caixa" Funding: 117900 Reference: 132074 Duration: 01/09/2023 - 31/08/2026
IP: Maria Buti Ferret Collaborators: Maria Francesca Cortese Funding agency: Instituto de Salud Carlos III Funding: 220000 Reference: PI23/01065 Duration: 01/01/2024 - 31/12/2026
IP: Juan Manuel Pericàs Pulido Collaborators: Alba Maria Jiménez Masip, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 65000 Reference: CM23/00251 Duration: 02/01/2024 - 01/01/2026
PhD student: Elena Vargas Accarino, Elena Vargas Accarino Director/s: Beatriz Minguez Rosique, Maria del Mar Riveiro Barciela University: Year: 2023
PhD student: Jesus Manuel Rivera Esteban Director/s: Salvador Augustin Recio University: Year: 2023
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
This tool will help avoid invasive techniques and assist in selecting candidates for clinical trials of new treatments.
Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.
